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Cystic fibrosis (CF) occurs in all South Africa’s population 
groups. While well described in the white and coloured 
populations, its presence in black African populations is less 
well known. Recent evidence from the group of CF patients 
in the Western Cape suggests an incidence of 1 in 3 000 and 
1 in 10 300 live births in the white and coloured populations 
respectively.1 In black South African populations, carrier 
frequency estimates have been used to project an incidence of 
1 in 4 624 live births.2 Further evidence of the presence of CF in 
these populations is presented in this issue of the Journal.3  
   While considering or being aware of the diagnosis is the 
first step in identifying CF, diagnosing the disease presents 
challenges at clinical and laboratory levels in South Africa.  
In simple terms, the diagnosis of CF requires a patient to 
have suggestive clinical features as well as 2 positive sweat 
tests and/or 2 identified disease-causing CF transmembrane 
conductance regulator (CFTR) gene mutations.  
   The classic triad of clinical features associated with CF 
consists of recurrent or persistent respiratory symptoms, 
pancreatic insufficiency and poor weight gain. A recent study 
of 181 CF patients in South Africa showed that only 4.6% of 
patients had all 3 features at presentation.  Only one-third had 
recognised malnutrition and one-third of patients did not have 
respiratory symptoms at the time of diagnosis.4 The range 
of symptoms that may suggest CF is very wide. In the fetus 
or neonate there may be intestinal obstruction; infants may 
present with anaemia and oedema, hypochloraemic metabolic 
alkalosis, rectal prolapse, severe ‘bronchiolitis’, or conjugated 
hyperbilirubinaemia; children may have nasal polyposis or 
uncontrolled ‘asthma’; adults may present with bronchiectasis, 
chronic obstructive airways disease, recurrent pancreatitis 
or infertility.5 Therefore only thinking of CF in certain ethnic 
groups or when features of the classic triad of CF are present 
will result in too low an index of suspicion for CF in South 
Africa.
   Once CF is suspected, the diagnosis should be confirmed 
or refuted. In South Africa, reliable sweat testing, the gold 
standard, is only available in major centres and it can be 
difficult to collect enough sweat in young infants.  Molecular 
testing for CFTR gene mutations is often requested as a 
substitute.  Without testing for multiple mutations, molecular 
testing in South African subjects is usually insufficiently 
sensitive to identify the diagnostic 2 CFTR mutations in true 
cases of CF.6 Even the most clear-cut scenario – testing for 
the commonest mutation in white persons, namely deltaF508 
– yields a diagnostic genotype (deltaF508/deltaF508) in 
only 58% of white CF patients.6 If molecular testing is to be 
done, the South African panel of mutations as described in 
Goldman et al.6 should be tested for. These mutations (from 
the more than 1 100 identified worldwide) have been shown 
to give the best results in South Africa at present, although 
further mutation detection studies are necessary to improve 
the detection rate in coloured and black African CF patients 
where the current mutation detection rates with the panel 
are 74% and 46%, respectively. Even using the panel, 16% of 
white CF patients, 38% of coloured CF patients and 50% of 
black CF patients will only have 1 identifiable CFTR mutation 
and some will have no mutation identified.6 Therefore the 
inability to identify 2 disease-causing CFTR mutations does 
not exclude the diagnosis of CF. Requesting molecular analysis 
instead of doing a sweat test may confirm a diagnosis of CF, 
but cannot exclude it.  Molecular testing should be performed 
by a laboratory familiar with genetic testing, and in particular 
CF molecular testing, as the methodology and standardisation 
used and the interpretation of the result are crucial. Sweat 
testing that includes a chloride estimation must remain the 
gold standard for the diagnosis in South Africa.7 With the 
increasing evidence that CF occurs at a significant frequency 
throughout South Africa, sweat testing needs to be made more 
available. The accuracy of sweat conductivity in confirming the 
diagnosis of CF is unproven7 but it may be a useful screening 
test.
   If molecular testing is done, the following potentially 
perplexing or problematic scenarios may confront the clinician. 
Only 1 CFTR gene mutation may be identified. There are 3 
possibilities in this situation.  
   In the first scenario the patient has typical CF. Genetically 
such a patient is a compound heterozygote, having a different 
mutation in each of the 2 CFTR genes, only one of which 
is identified by molecular testing. In this situation, CF can 
and should be confirmed with a sweat test.  Because of the 
importance of accurate diagnosis, the case should be discussed 
with an expert in CF, especially if sweat testing is not available. 
Pancreatic insufficiency, present in about 85% of typical CF 
cases, can be proved by testing a stool sample for faecal 
human pancreatic elastase-1.8 Typical micro-organisms such as 
Pseudomonas aeruginosa and Staphylococcus aureus may be found 
in respiratory secretions.  
   In the second scenario, the patient has atypical CF.  In 
this situation, the patient often has mild symptoms and 
equivocal sweat test results.  This patient is also a compound 
heterozygote but the unidentified mutation is responsible 
for the mild phenotype.  The World Health Organization has 
classified a number of CFTR-associated clinical syndromes, 
only 2 of which are ‘typical’ CF.9 Again, such a patient should 
be discussed with an expert in CF. Sophisticated testing may be 
the only way to confirm the diagnosis.  Symptomatic treatment, 
careful genetic counselling and follow-up are required.
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   The third scenario is that the patient has another disease and 
carries a CFTR mutation.  Except in occasional cases of atypical 
CF, sweat electrolyte levels are rarely normal in CFTR-related 
disease. Carriers of a CFTR mutation have normal sweat 
electrolyte levels. The patient is identified as at risk of having 
a child with CF. This information should only be given to the 
patient in association with genetic counselling.  If the patient is 
a child, the parents should be told that the testing has excluded 
CF. The child’s carrier status should not be revealed to the 
parents. 
   Since molecular testing always carries the possibility of 
revealing carrier status, this situation should be anticipated 
and discussed with the child’s parents before the test is done.  
The right of the child to decide in the future whether or not to 
know his or her carrier status at a time of his or her choosing 
is taken as paramount in current guidelines on the molecular 
testing of children.10,11 These guidelines are based on the ethical 
principle of non-maleficence, the presumption being, in the 
absence of clear evidence to the contrary,12 that harms are 
likely to outweigh benefits in these situations. They also reflect 
the primacy of the best interests of the child as set out in the 
Convention on the Rights of the Child and the South African 
Constitution. Autonomy is another ethical principle that would 
be circumvented if such information were provided before 
the child was able to decide what he or she wished to know. 
Therefore the practitioner should counsel the parents on the 
purpose of the test, namely to confirm the diagnosis of CF. If 
fewer than 2 mutations are identified the test has simply not 
confirmed the diagnosis.  The practitioner will need to decide 
whether it is appropriate to take the issue further with the 
patient when he or she grows up.
   Practitioners in almost all fields of medicine in South Africa 
need to consider CF in the differential diagnosis of all patients 
presenting with common symptoms. The diagnosis should 
be confirmed with a sweat test and not by sweat conductivity 
alone. Molecular testing should include the South African 
panel of CFTR gene mutations as appropriate for the ‘ethnic’ 
origin of the patient. The potential meaning of the results 
of such testing in different clinical situations needs to be 
understood.
   The South African Cystic Fibrosis Consensus Document is 
available from the South African Cystic Fibrosis Association, 
PO Box 16891, Atlasville 1465. 
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